Insider Trading April 21, 2026 04:23 PM

Astera Labs director sells $4.38 million in stock under 10b5-1 plan

Stefan Dyckerhoff executed two scheduled sales totaling 24,998 shares as the stock trades well above fair value estimates ahead of earnings

By Nina Shah ALAB
Astera Labs director sells $4.38 million in stock under 10b5-1 plan
ALAB

Stefan A. Dyckerhoff, a director at Astera Labs Inc. (NASDAQ: ALAB), sold 24,998 shares of common stock on April 17 and April 20, 2026, under a Rule 10b5-1 trading arrangement adopted December 1, 2025. The disposals amounted to $4,376,257 at prices between $175.00 and $175.51 per share. The transactions occurred as ALAB shares have risen 223% over the prior year and trade above InvestingPro's Fair Value assessment; the company reports results on May 5, 2026.

Key Points

  • Director Stefan A. Dyckerhoff sold 24,998 Astera Labs shares on April 17 and April 20, 2026, for total proceeds of $4,376,257 under a Rule 10b5-1 plan adopted December 1, 2025.
  • ALAB shares have climbed 223% over the past year, trading at $192.02 with a market capitalization of $32.75 billion, and InvestingPro places the stock on its Most Overvalued list.
  • Astera Labs reported Q4 2025 EPS of $0.58 on revenue of $270.6 million, up 92% year over year; RBC and UBS issued divergent price targets and ratings tied to expected product-driven revenue and evolving market adoption.

Transaction overview

Stefan A. Dyckerhoff, who serves on the board of Astera Labs, Inc. (NASDAQ: ALAB), completed planned sales of company stock on April 17 and April 20, 2026. The two sets of transactions together covered 24,998 shares of common stock and generated total proceeds of $4,376,257. The per-share prices for the trades ranged from $175.00 to $175.51. Mr. Dyckerhoff executed these sales pursuant to a Rule 10b5-1 trading plan he adopted on December 1, 2025.


Details by date and vehicle

On April 17, Mr. Dyckerhoff sold 11,599 shares. That day's activity comprised three components: 3,253 shares sold directly by Mr. Dyckerhoff, 7,733 shares sold indirectly through a trust, and 613 shares sold indirectly via a limited partnership. The prices for the April 17 trades ranged from $175.00 to $175.01 per share.

Following the April 17 transactions, his holdings were recorded as 70,901 shares held directly, 345,331 shares held indirectly through a trust, and 7,323 shares held indirectly through a limited partnership.

On April 20, Mr. Dyckerhoff sold an additional 13,399 shares. That day's breakdown included 3,757 shares sold directly, 8,933 shares sold indirectly through a trust, and 709 shares sold indirectly through a limited partnership. The prices for the April 20 trades ranged from $175.02 to $175.51 per share.

After closing the April 20 transactions, Mr. Dyckerhoff's reported holdings stood at 67,144 shares directly, 336,398 shares indirectly through a trust, and 6,614 shares indirectly through a limited partnership.


Market context and valuation

The insider sales occurred while ALAB shares have advanced 223% over the past year. At the time of the reporting, the stock was trading at $192.02 and the company carried a market capitalization of $32.75 billion. Analysis from InvestingPro indicated the stock appears overvalued relative to its Fair Value and placed the company on its Most Overvalued list.

Investors tracking the company also face a near-term corporate event: Astera Labs is scheduled to report quarterly results in 14 days, with the earnings release set for May 5, 2026.


Recent financial results and analyst commentary

Astera Labs reported strong fourth-quarter 2025 results, delivering earnings per share of $0.58 versus analyst expectations of $0.51. Quarterly revenue reached $270.6 million, a year-over-year increase of 92%.

On the analyst front, RBC Capital raised its price target for Astera Labs stock to $250 while keeping an Outperform rating. RBC cited expected growth tied to Trainium3-related Scorpio-X switch revenue, which is projected to begin in the third quarter of 2026.

Separately, UBS initiated coverage of Astera Labs with a Neutral rating and set a price target of $180. Analyst Natalia Winkler remarked that the company has become a credible AI networking supplier over the past five years and has broadened its customer base beyond its initial anchor customer, Amazon Web Services, expanding adoption among additional hyperscalers.


Where to find more company research

For investors seeking further valuation context and financial detail, a comprehensive Pro Research Report is available for this company and for more than 1,400 other U.S. equities.


Note on presentation

This article presents transaction-level details reported for a director of Astera Labs, company financial results released for the fourth quarter of 2025, and analyst ratings and price targets as stated above. The timeline and numbers included reflect the information provided relating to the insider sales, the company's recent operating results, and analyst commentary.

Risks

  • Valuation risk: InvestingPro analysis classifies ALAB as overvalued relative to Fair Value, placing it on the Most Overvalued list - this affects equity market participants and investors.
  • Earnings timing risk: The company is due to report earnings on May 5, 2026, creating near-term uncertainty for shareholders and market-moving potential for the stock.
  • Analyst divergence: Differing analyst views and price targets - RBC's $250 Outperform and UBS's $180 Neutral - reflect uncertainty about near-term growth drivers and their timing, which can influence investor sentiment in AI networking and semiconductor supply chains.

More from Insider Trading

Venture Global CFO Disposes of $2.6 Million in Class A Shares After Exercising Options Apr 21, 2026 Porch Group CEO Completes $896K Share Sale to Cover PRSU Taxes Apr 21, 2026 Core & Main CFO Completes 5,000-Share Sale Under 10b5-1 Plan; Company Reports Q4 EBITDA In Line With Estimates Apr 21, 2026 SiTime Executive Disposes $1.17 Million in Shares Amid Elevated Stock Price Apr 21, 2026 Porch Group COO Sells $464,286 in Shares in Sell-to-Cover Transaction Apr 21, 2026